Clinical trials
Churg-Strauss Syndrome trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
13 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Completed | 3 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| European EGPA Study Group | 2 |
| GlaxoSmithKline | 2 |
| Azienda Ospedaliero Universitaria di Cagliari | 1 |
| Fondazione IRCCS Policlinico San Matteo di Pavia | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| NS Pharma, Inc. | 1 |
| University of Oxford | 1 |
| University of Parma | 1 |
| University of Pennsylvania | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Churg-Strauss Syndrome | 13 |
| Vasculitis | 3 |
| Asthma | 2 |
| Granulomatosis with Polyangiitis | 2 |
| Hypereosinophilic Syndrome | 2 |
| Microscopic Polyangiitis | 2 |
| Polyarteritis Nodosa | 2 |
| Giant Cell Arteritis | 1 |
| Paranasal Sinus Diseases | 1 |
| Pulmonary Eosinophilia | 1 |
Trials
Showing 26 to 13 of 13. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.